Omalizumab, an anti‐immunoglobulin (Ig)E monoclonal antibody, has been shown to increase the threshold for hypersensitivity reactions by preventing IgE cross‐linking on mast cells (MCs), leading to downregulation of surface IgE receptors, demonstrating utility in idiopathic anaphylaxis, hereditary alpha tryptasemia (HαT), food allergy, and further improving safety in desensitization via oral immunotherapy [47, 48, 49, 50, 51]. The gene discussed is IGHE; the disease is idiopathic anaphylaxis.